

SEP 01 2006

Response and Amendment
Docket No. 2301-M

Immunex Corporation

Amendment to the Specification

Please replace the paragraph beginning at page 1, line 6, with the following rewritten paragraph:

This is a divisional of application Serial No. 10/104,590, filed March 22, 2002, now allowed U.S. Patent 6,716,587, which is a divisional of application Serial No. 09/094,917, filed June 15, 1998, now U.S. Patent 6,391,581, which is a continuation of application Serial No. 07/480,694, filed February 14, 1990, now U.S. Patent 5,840,869, which is a continuation-in-part of application Serial No. 07/370,924, filed June 23, 1989, abandoned, which is a continuation-in-part of Serial No. 07/326,156, filed March 20, 1989, abandoned, which is a continuation-in-part of Serial No. 07/319,438, filed March 2, 1989, abandoned, which is a continuation-in-part of Serial No. 07/265,047, filed October 31, 1988, abandoned.

Please replace the Abstract of the Disclosure (page 49, lines 7-11) with the following amended paragraph:

~~Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4 dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.~~

Methods and compositions related to antibodies that bind to mammalian Interleukin-4 receptor proteins are disclosed.